Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ
Advisors Preferred LLC recently acquired a new stake of 20,861 shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), valued at approximately $5.079 million. Other institutional investors have also adjusted their positions in the company, which saw its stock open at $248.70 with a market cap of $16.15 billion. The pharmaceutical company recently missed analysts' consensus earnings estimates but reported a 15.5% increase in revenue year-over-year.
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative
Jazz Pharmaceuticals (JAZZ) is gaining investor attention due to its HER2 pipeline progress, particularly for gastroesophageal adenocarcinoma, and is currently deemed 11.6% undervalued with a fair value of $281.35. Despite a recent share price pullback, the company shows strong year-to-date and one-year returns, driven by R&D, commercialization efforts, and international expansion, although potential risks like generic pressure and trial underperformance exist.
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative
Jazz Pharmaceuticals (JAZZ) is gaining investor interest due to its progress in HER2 pipeline development for cancers, leading to a 106.3% one-year total shareholder return. Despite a recent slight share price pullback, the company is considered 11.6% undervalued with a fair value of $281.35, driven by rare-disease pricing, a maturing neuroscience franchise, and international oncology scaling. Investors should also consider risks like generic drug pressure and trial underperformance.
Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ
Great Lakes Advisors LLC has acquired a new stake of $8.15 million in Jazz Pharmaceuticals PLC, purchasing 33,804 shares in the second quarter. This move makes Great Lakes Advisors LLC own approximately 0.05% of the company's stock. The article also details recent insider stock sales, other hedge fund activities, analyst ratings, and the company's financial performance.
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks
This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (J7Z). It provides detailed information for each ETF, including market value, weight of J7Z stock, issuer, management style, focus, expense ratio, assets under management (AUM), current price, percentage change, relative volume, and 3-year NAV total return. The ETFs cover different market segments such as mid-cap, total market, small-cap, extended market, large-cap, and healthcare, offering diverse investment opportunities with varying risk profiles.
Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion
Irish biopharmaceutical company Jazz Pharmaceuticals plc has announced its acquisition of American Actio Biosciences, Inc. for $1.32 billion. The deal involves an upfront payment of $820 million and an additional $500 million contingent on drug approval and sales milestones. Jazz will gain control of ABS-1230, a drug for a rare form of childhood epilepsy, while Actio Biosciences will form a new independent company focusing on rare genetic neurological diseases.
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 96.7% in the second quarter, selling 309,427 shares and retaining 10,573 shares valued at $2.55 million. Despite this, institutional investors and hedge funds collectively own 89.14% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $272.89. The company reported quarterly revenue of $1.21 billion, exceeding estimates, though adjusted EPS missed consensus.
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed
Jazz Pharmaceuticals (JAZZ) stock has shown a significant return of 112.6% over the past year. Despite this performance and recent deal activity, the stock appears undervalued based on its P/E ratio of 17.2x, which is on par with the industry average but significantly lower than a peer group average of 28.8x and its estimated fair P/E of 24.7x. The market's current valuation of JAZZ suggests a mixed picture, not a clear bargain, with the company's ability to execute on its pipeline and manage risks being key to future performance.
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ
Wedge Capital Management L L P NC reduced its stake in Jazz Pharmaceuticals PLC by 20.9% in the second quarter, selling 33,467 shares and retaining 126,539 shares valued at approximately $30.5 million. Despite missing quarterly EPS estimates, the company's revenue exceeded expectations, and analysts generally maintain a "Moderate Buy" rating with an average target price of $272.89. The article also highlights recent insider selling activity and the company's strategic acquisition of Actio Biosciences to expand its rare epilepsy portfolio, a move seen as strategically sensible but with inherent clinical development and commercialization risks.
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for an upfront payment of $820 million, with potential additional contingent payments of up to $500 million. This deal includes Actio Biosciences spinning out a new company focused on genetic rare neurological diseases, in which Jazz will hold a minority equity interest. The acquisition significantly expands Jazz's rare epilepsy portfolio with Actio's main clinical asset, ABS-1230, a small molecule inhibitor for KCNT1+ epilepsy, which has secured FDA fast track, rare pediatric disease, and orphan drug product designations.
Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ
Royal Bank of Canada increased its stake in Jazz Pharmaceuticals PLC by 17.4% in the first quarter, now holding 45,251 shares valued at $8.56 million. Institutional investors collectively own 89.14% of JAZZ shares, reflecting positive sentiment despite a recent EPS miss. Jazz Pharmaceuticals reported strong revenue growth and raised its 2026 outlook, maintaining a "Moderate Buy" consensus rating among analysts.
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a private biotech specializing in genetic epilepsy treatments, for an upfront payment of $820 million and potential milestone payments of $500 million, totaling $1.3 billion. The acquisition will bolster Jazz's neuroscience pipeline, particularly with Actio's lead drug candidate, ABS-1230, which targets a rare form of epilepsy caused by KCNT1 gene mutations and is currently in a 55-participant study. This deal reflects a broader trend of increased private biotech buyouts, with Jazz leveraging its cash reserves and existing financing to fund the transaction.
Jazz Pharmaceuticals to Acquire Actio Biosciences in Deal Worth Up to $1.32 Billion
Jazz Pharmaceuticals is set to acquire Actio Biosciences in a deal valued at up to $1.32 billion, significantly expanding its rare epilepsy portfolio. The acquisition centers on ABS-1230, Actio's clinical-stage precision medicine for KCNT1-related epilepsy, a rare genetic disorder. The deal includes an $820 million upfront payment and up to $500 million in milestone payments, with Actio spinning out its other pipeline assets into a new independent company.
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M
Jazz Pharmaceuticals announced its acquisition of Actio Biosciences for an upfront payment of $820 million, with potential additional payments of up to $500 million tied to milestones. The acquisition is primarily focused on ABS-1230, a clinical-stage drug for KCNT1+ epilepsy, a rare genetic disorder with no currently approved therapies. Actio Biosciences will spin off a new entity for other neurological diseases, in which Jazz will hold a minority stake.
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio
Jazz Pharmaceuticals (JAZZ) announced its acquisition of Actio Biosciences for $820 million upfront and up to $500 million in milestone payments, expected to close by late 2026. This strategic move strengthens Jazz's rare epilepsy portfolio with the addition of ABS-1230, a promising therapy for ultra-rare KCNT1+ epilepsy. Actio's other genetic neurology assets will be spun out into a new private company where Jazz will hold a minority stake.
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history
This article provides a detailed overview of Jazz Pharmaceuticals plc (JAZZ), including its stock price, news, and historical data. It covers the company's financial performance, product pipeline, analyst ratings, and compares it with similar biotechnology companies. The information presented aims to give investors a comprehensive look at JAZZ's market position and prospects.
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Jazz Pharmaceuticals PLC (JAZZ), highlighting its current earnings forecast score, average price target, and analyst ratings. It details expected future EPS and revenue growth, along with recent performance and a peer comparison. The forecast indicates a "Buy" trend based on analyst consensus, with an expected revenue of $1.21 billion for the next quarter.
Jazz Pharmaceuticals plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:JAZZ) 2026-08-07
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $5.71, missing estimates by $0.47, but revenue reached $1.21 billion, surpassing expectations by $93.90 million with a 15.55% year-over-year increase. This presentation provides stakeholders with key financial insights from the recent quarter.
Jazz Pharmaceuticals plc SEC Filing (Aug 7, 2026)
Jazz Pharmaceuticals plc has filed a Form 144 SEC filing on August 7, 2026, concerning a proposed sale of securities. The filing indicates a neutral impact and sentiment according to AI-generated analysis by StockTitan. It details information about the issuer, the filer (Etrade Financial Corporation), and the securities to be sold, which include 3,507 shares of common stock acquired through restricted stock vesting.
Jazz Pharmaceuticals plc (JAZZ) News, Articles, Events & Latest Updates
Jazz Pharmaceuticals (JAZZ) reported strong Q2 2026 results, exceeding sales estimates and raising its 2026 revenue guidance, despite an EPS miss. The company's performance was driven by robust demand in its oncology and neuroscience segments, leading to a stock jump and mixed analyst reactions, with some increasing price targets. This makes JAZZ a potential top momentum and value stock according to Zacks Style Scores.
Jazz Pharmaceuticals Plc Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals Plc recently reported its quarterly earnings, missing analyst EPS estimates by 13%. This article discusses the company's latest financial results and provides an overview of how analysts are adjusting their future earnings and revenue forecasts in light of this performance. It highlights the consensus price target and the potential implications for the stock's future valuation.
FMR LLC and Abigail Johnson disclose 7.4% Jazz Pharmaceuticals (JAZZ) ownership
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 7.4% of Jazz Pharmaceuticals plc common stock, according to a SCHEDULE 13G SEC filing. FMR LLC holds 4,675,458.82 shares, with sole voting power over 4,618,210.03 shares and sole dispositive power over all its shares. Abigail Johnson also reports sole dispositive power over the same number of shares but no voting power, indicating a significant passive investment in the company.
Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Sh
Jazz Pharmaceuticals Director Bruce Cozadd sold 6,000 shares of JAZZ for approximately $1.52 million, bringing his total sales over the past year to 143,000 shares with no purchases. This insider selling activity, combined with the stock trading significantly above its GF Value (price-to-GF-Value ratio of 1.66), suggests the company may be overvalued despite a lower-than-industry average P/E ratio. Investors are advised to consider these signals carefully, as consistent insider selling often indicates that those closest to the company believe the current valuation may not fully reflect its risks or growth prospects.
Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Shares
Bruce Cozadd, a director at Jazz Pharmaceuticals (JAZZ), sold 6,000 shares for approximately $1.52 million on August 3, 2026. This sale contributes to a pattern of 27 insider sells versus zero buys over the last year, suggesting insiders are reducing their exposure. The stock is currently trading at $252.98, significantly above its GuruFocus GF Value of $152.38, indicating it is overvalued.
Jazz Pharmaceuticals (JAZZ) Stock May Stay Below Fair Value Following Raised Guidance
Jazz Pharmaceuticals' stock has seen a significant surge over the past year, returning 146.9%. Despite this, the company's valuation metrics, particularly its P/E ratio of 18.0x, suggest it might still be undervalued compared to a tailored reference multiple of 24.7x, even after record Q2 2026 revenue and raised guidance. The article explores both bullish and bearish cases for the stock, highlighting the importance of pipeline execution and margin improvements for future upside.
Jazz Pharmaceuticals stock hits all-time high at 261.46 USD
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $261.46, marking a 130.32% increase over the past year. This growth is attributed to strong investor confidence, strategic initiatives, and robust financial results, including a Q2 revenue beat driven by key product performances. Several analysts have raised their price targets for the company following these positive developments.
Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $285, Implies 13% Upside
Jazz Pharmaceuticals plc's average 12-month price target has been increased from $270.63 to $285 by 19 analysts, suggesting a 13% potential upside from its August 3rd closing price. The consensus rating for JAZZ stock remains a "Buy" among 22 analysts, with 19 recommending Buy, 1 Hold, and 2 Sell.
Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push
Jazz Pharmaceuticals (JAZZ) saw its stock climb after reporting record Q2 revenue and raised full-year guidance, driven by strong performance in its neurology segment and progress in oncology. The company's Q2 revenue hit US$1.21 billion with non-GAAP EPS of US$5.71, leading to an increased full-year revenue forecast of US$4.60 billion to US$4.75 billion. This performance suggests successful cash generation and commercial execution, while the company continues its pivot towards oncology with products like Ziihera meeting key milestones.
Jazz Pharmaceuticals stock hits all-time high at 261.46 USD By Investing.com
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $261.46, marking a 130.32% increase over the past year. Despite trading near its 52-week high, InvestingPro analysis suggests the stock is undervalued. The company also reported strong second-quarter revenues of $1.21 billion, exceeding estimates, which has led several financial firms to raise their price targets for JAZZ.
California State Teachers Retirement System Grows Position in Jazz Pharmaceuticals PLC $JAZZ
The California State Teachers Retirement System increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 22% in the first quarter of 2026, now holding 63,657 shares valued at $12 million. Other institutional investors also significantly grew their positions. Analysts maintain a generally bullish outlook on Jazz Pharmaceuticals, with a consensus price target of $259.06 and multiple recent price target increases.
RBC Capital Adjusts Price Target on Jazz Pharmaceuticals to $273 From $258, Maintains Outperform Rating
RBC Capital has raised its price target for Jazz Pharmaceuticals (JAZZ) from $258 to $273, while reiterating an Outperform rating on the stock. This adjustment comes amidst other analyst updates for the biopharmaceutical company, including price target increases from Deutsche Bank and Morgan Stanley. Jazz Pharmaceuticals recently reported its Q2 2026 earnings, swinging to non-GAAP earnings and showing increased revenue, with a full-year 2026 revenue forecast between $4.60 billion and $4.75 billion.
What Jazz Pharmaceuticals’ Q2 Earnings Call Revealed About the Zanidatamab Bet
Jazz Pharmaceuticals reported a record Q2 revenue of $1.21 billion, a 16% year-over-year increase, prompting the company to raise its full-year revenue guidance. The strong performance was driven by significant growth in oncology sales and better-than-expected Xywav sales despite generic competition, attributed to strong field execution. The company is now keenly awaiting the August 25 FDA decision on zanidatamab, which could be a major catalyst for its oncology segment.
Q2 2026 Jazz Pharmaceuticals PLC Earnings Call Transcript
Jazz Pharmaceuticals PLC reported record quarterly revenue of $1.2 billion in Q2 2026, a 16% year-over-year increase, and raised its full-year 2026 revenue guidance to $4.60-$4.75 billion. Key drivers included strong performance from Xywav, Zepzelca, and Epidiolex, with a significant upcoming PDUFA date for Zanidatamab. The company also highlighted its robust pipeline and strong financial position, while acknowledging potential challenges from future competition and shifts in revenue streams.
Jazz Pharmaceuticals plc Q2 2026: Revenue $1156.1M, EPS $2.78— 10-Q Summary
Jazz Pharmaceuticals plc reported strong Q2 2026 results with revenue of $1156.1M and diluted EPS of $2.78, marking a significant improvement from the prior year's loss. Growth was fueled by key product performance, including Xywav and Epidiolex, and successful oncology launches. The company also increased R&D investments for late-stage programs, with a key sBLA PDUFA date set for August 25, 2026.
Jazz Pharmaceuticals (JAZZ) swings to H1 2026 profit and trims $1B in debt
Jazz Pharmaceuticals reported a significant financial turnaround in the first half of 2026, swinging to a net income of $485.9 million compared to a net loss of $811.0 million in the prior-year period. Revenues also increased to $2,277.2 million. The company successfully reduced its total debt by $1.0 billion through the repayment of 2026 exchangeable notes, demonstrating strong financial management and operational efficiency.
Jazz Pharmaceuticals plc (JAZZ) Earnings Preview
This article previews Jazz Pharmaceuticals plc's upcoming earnings report, highlighting the company's position as a global biopharmaceutical player in neuroscience and oncology. It emphasizes key challenges and opportunities, including the transition of its oxybate franchise, pipeline execution, and the need to sustain profitability amidst macroeconomic headwinds. The report suggests investors should focus on analyst expectations, product revenue trends, management guidance, and cash flow dynamics for a comprehensive understanding of the stock's future trajectory.
Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect
Jazz Pharmaceuticals (NASDAQ:JAZZ) is set to report Q2 earnings after market hours. Analysts anticipate a 6.7% year-on-year revenue growth, improving from 2.1% in the prior year. The company rarely misses Wall Street's revenue estimates and investors are holding steady, with an average analyst price target of $266.90.
JAZZ Looks 68.1% Overvalued on GF Value™
Jazz Pharmaceuticals (NASDAQ: JAZZ) is scheduled to report its second-quarter earnings on August 3rd, amidst an elevated Price-to-Sales ratio of 3.55, suggesting it is 68.1% overvalued according to its GF Value™. Despite a strong GF Score of 73 highlighting profitability and growth, concerns are raised by insider selling and mixed analyst revisions, prompting investors to carefully weigh the company's growth potential against its current high valuation.
Precision Trading with Jazz Pharmaceuticals Plc (JAZZ) Risk Zones
This article provides a precision trading analysis for Jazz Pharmaceuticals Plc (JAZZ), highlighting strong sentiment across all horizons and tested resistance levels. It outlines specific institutional trading strategies, including long, breakout, and short setups with defined entry, target, and stop-loss zones. The analysis is supported by multi-timeframe signal data and AI-generated signals.
Jazz Pharmaceuticals PLC (JAZZ) Financial Health: Profitability & Balance Sheet Analysis
Jazz Pharmaceuticals PLC (JAZZ) has a stable financial score of 8.58, ranking 40th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 19.05% year-over-year revenue increase to $1.07 billion and a remarkable 416.72% increase in net profit. While its overall financial health is stable, specific data for quality of earnings, operational efficiency, growth potential, and shareholder returns have not been fully disclosed for detailed analysis.
Should Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals (JAZZ) Investors?
Jazz Pharmaceuticals (JAZZ) is projected to report a significant year-over-year earnings increase for Q2 2026 and recently received a Gold Stevie Award for Employer of the Year, indicating strong operational performance and a positive workplace culture. While these factors boost near-term confidence, investors should consider the company's broader investment narrative, which includes managing patent expirations, high debt, and the need for successful commercialization of new oncology assets to offset potential erosion in its oxybate sleep franchise. Analysts' varied forecasts highlight the importance of evaluating both optimistic earnings outlooks and the inherent risks.
Should Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals (JAZZ) Investors?
Jazz Pharmaceuticals is anticipating a strong Q2 2026 earnings beat with a significant year-over-year increase, coupled with receiving a Gold Stevie Award for Employer of the Year. While these positives indicate operational momentum and a supportive workplace culture, investors should also consider risks like patent expirations affecting its oxybate sleep franchise and the need for successful commercialization of new oncology assets to sustain long-term growth. The article suggests focusing on the company's full investment narrative, including projected revenues and earnings, to form a comprehensive investment decision.
Jazz Pharmaceuticals (JAZZ) Projected to Announce Earnings on Monday
Jazz Pharmaceuticals (JAZZ) is expected to report its Q2 2026 earnings after market close on Monday, August 3rd, with analysts projecting $6.18 EPS and $1.114 billion in revenue. The company's stock has risen, trading near its 12-month high with a "Moderate Buy" consensus from analysts. Insider sales of 13,098 shares occurred in the last three months, while institutional investors own a significant majority of the company.
Castleark Management LLC Invests $9.21 Million in Jazz Pharmaceuticals PLC $JAZZ
Castleark Management LLC has acquired a new stake worth $9.21 million in Jazz Pharmaceuticals PLC, purchasing 48,740 shares in the first quarter. This investment, along with other institutional activity, indicates strong institutional interest, with 89.14% of the stock owned by hedge funds and other institutional investors. Analysts generally maintain a positive outlook, with a consensus "Moderate Buy" rating and an average price target of $259.06.
Jazz Pharmaceuticals PLC (JAZZ) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on Jazz Pharmaceuticals PLC (JAZZ) stock performance, showing a closing price of $255.440 and a market cap of $15.69 billion. It notes that the company has not distributed any dividends over the past five years. The page also includes current trading data and general corporate information.
Jazz Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
As of March 2026, Jazz Pharmaceuticals Plc has approximately 2,914 employees worldwide, an increase from 2,878 employees in 2023. The company is actively hiring, with 244 active job postings in 2026, a 56.2% increase from 2025. The workforce is concentrated in North America (50.0%), and the average salary is $155,724, with North America having the highest median pay.
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Cheap As Shares Jumped 115%
Jazz Pharmaceuticals (JAZZ) has seen a significant 115% share price increase over the last year, yet Simply Wall St's analysis suggests it remains undervalued on several metrics, particularly its P/S ratio. While the company's revenue growth and product pipeline support optimism, potential risks like patent expirations and pricing pressures are considered in "Bear Case" narratives that could affect its valuation. The market currently presents a mixed picture, leaving investors to weigh the discount against these inherent risks.
TradingKey
This article provides a detailed cash flow statement for Jazz Pharmaceuticals PLC (JAZZ) across numerous quarters and fiscal years. It includes operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The data is presented with year-over-year percentage changes and absolute monetary values, allowing for a comprehensive analysis of the company's financial liquidity and performance.
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Cheap As Shares Jumped 115%
Jazz Pharmaceuticals (JAZZ) stock has seen a significant 115% jump over the past year, yet Simply Wall St's valuation checks present a mixed picture, suggesting it's not a clear bargain or clearly overvalued. While the company screens as undervalued on 4 of 6 measures overall, implying some valuation support, the P/S ratio of 3.6x compared to a fair P/S of 7.9x suggests the stock trades at a sizeable discount. Investors are now focused on whether its revenue growth and product pipeline can justify a higher sales multiple or if risks like patent expirations and pricing pressures will limit future upside.
Jazz Pharmaceuticals plc Revenue Breakdown – NASDAQ:JAZZ
Jazz Pharmaceuticals plc generated $4.27 billion USD last year, primarily from its Pharmaceutical Products segment. This represents an increase from $4.07 billion USD in the previous year. The United States was the largest contributor to revenue, accounting for $3.83 billion USD.
